Your browser doesn't support javascript.
loading
Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor.
Zheng, Barbara; D'Andrea, Stanley V; Sun, Li-Qiang; Wang, Alan Xiangdong; Chen, Yan; Hrnciar, Peter; Friborg, Jacques; Falk, Paul; Hernandez, Dennis; Yu, Fei; Sheaffer, Amy K; Knipe, Jay O; Mosure, Kathy; Rajamani, Ramkumar; Good, Andrew C; Kish, Kevin; Tredup, Jeffrey; Klei, Herbert E; Paruchuri, Manjula; Ng, Alicia; Gao, Qi; Rampulla, Richard A; Mathur, Arvind; Meanwell, Nicholas A; McPhee, Fiona; Scola, Paul M.
Afiliação
  • Zheng B; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • D'Andrea SV; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Sun LQ; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Wang AX; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Chen Y; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Hrnciar P; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Friborg J; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Falk P; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Hernandez D; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Yu F; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Sheaffer AK; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Knipe JO; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Mosure K; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Rajamani R; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Good AC; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Kish K; Research and Development, Bristol-Myers Squibb, PO Box 5400, Princeton, New Jersey 08543, United States.
  • Tredup J; Research and Development, Bristol-Myers Squibb, PO Box 5400, Princeton, New Jersey 08543, United States.
  • Klei HE; Research and Development, Bristol-Myers Squibb, PO Box 5400, Princeton, New Jersey 08543, United States.
  • Paruchuri M; Biologics Process Development, Bristol-Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, New Jersey 08534, United States.
  • Ng A; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Gao Q; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Rampulla RA; Discovery Synthesis, Research and Development, Bristol-Myers Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543, United States.
  • Mathur A; Discovery Synthesis, Research and Development, Bristol-Myers Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543, United States.
  • Meanwell NA; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • McPhee F; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • Scola PM; Research and Development, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
ACS Med Chem Lett ; 9(2): 143-148, 2018 Feb 08.
Article em En | MEDLINE | ID: mdl-29456803
ABSTRACT
The design and synthesis of potent, tripeptidic acylsulfonamide inhibitors of HCV NS3 protease that contain a difluoromethyl cyclopropyl amino acid at P1 are described. A cocrystal structure of 18 with a NS3/4A protease complex suggests the presence of a H-bond between the polarized C-H of the CHF2 moiety and the backbone carbonyl of Leu135 of the enzyme. Structure-activity relationship studies indicate that this H-bond enhances enzyme inhibitory potency by 13- and 17-fold compared to the CH3 and CF3 analogues, respectively, providing insight into the deployment of this unique amino acid.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article